Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
Saved in:
| Title: | Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. |
|---|---|
| Authors: | Ngo HX; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA., Xu AY; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.; Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA., Velásquez GE; UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA.; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA., Zhang N; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA., Chang VK; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA., Kurbatova EV; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Whitworth WC; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Sizemore E; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Bryant K; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Carr W; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Weiner M; University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Care System, San Antonio, Texas, USA., Dooley KE; Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Engle M; University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Care System, San Antonio, Texas, USA., Dorman SE; Medical University of South Carolina, Charleston, South Carolina, USA., Nahid P; UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA., Swindells S; University of Nebraska Medical Center, Omaha, Nebraska, USA., Chaisson RE; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Nsubuga P; Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda., Lourens M; TASK Applied Science CRS, Brooklyn Chest Hospital, Bellville, South Africa., Dawson R; Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Savic RM; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1680-1689. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
